Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03012971
NA

Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery

Sponsor: Peking University First Hospital

View on ClinicalTrials.gov

Summary

A majority of the elderly patients undergo surgery for malignant tumors. For these patients, postoperative tumor recurrence and metastasis are main factors that worsen long-term outcomes. The investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may help to maintain immune function and improve long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.

Official title: Impact of Dexmedetomidine Supplemented Analgesia on Long-term Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial

Key Details

Gender

All

Age Range

65 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

1500

Start Date

2017-01-06

Completion Date

2026-12-11

Last Updated

2026-07-28

Healthy Volunteers

No

Interventions

DRUG

Dexmedetomidine supplemented morphine analgesia

Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.

DRUG

Morphine analgesia

Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.

Locations (12)

Peking University First Hospital

Beijing, Beijing Municipality, China

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Beijing, Beijing Municipality, China

Peking University International Hospital , , China, Contact:

Beijing, Beijing Municipality, China

Chongqing University Fuling Hospital

Chongqing, Chongqing Municipality, China

Guizhou Provincial People's Hospital , China, Contact:

Guiyang, Guizhou, China

Affiliated Hospital of Hebei University

Baoding, Hebei, China

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

The Second Affiliated Hospital of Air Force Medical University

Xi'an, Shaanxi, China

Qingdao Municipal Hospital , , China, Contact:

Qingdao, Shandong, China

Shanxi Provincial Cancer Hospital , China, Contact:

Taiyuan, Shanxi, China

Tianjin Hospital of ITCWM-Nankai Hospital

Tianjin, Tianjin Municipality, China

The Third Central Hospital of Tianjin

Tianjin, Tianjin Municipality, China